Zheng Wang1, Samantha A Molsberry, Yu Cheng, Lawrence Kingsley, Andrew J Levine, Eileen Martin, Cynthia A Munro, Ann Ragin, Leah H Rubin, Ned Sacktor, Eric C Seaberg, James T Becker. 1. aDepartment of Statistics bDepartment of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania cPopulation Health Sciences, Harvard University, Cambridge, Massachusetts dDepartment of Epidemiology eDepartment of Infectious Diseases and Microbiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania fDepartment of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, California gDepartment of Psychiatry, Rush University School of Medicine, Chicago, Illinois hDepartment of Psychiatry iDepartment of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland jDepartment of Radiology, Northwestern University, Evanston, Illinois kDepartment of Epidemiology, Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, Maryland lDepartment of Psychiatry mDepartment of Neurology nDepartment of Psychology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Abstract
BACKGROUND: Prevalence estimates of cognitive impairment in HIV disease vary widely. Here we used multivariate normative comparison (MNC) with identify individuals with impaired cognition, and to compare the results with those using the Frascati and Gisslén criteria. METHODS: The current project used data collected before October 2014 from bisexual/gay men from the Multicenter AIDS Cohort Study. A total of 2904 men (mean age 39.7 years, 52.7% seropositive) had complete data in six cognitive domains at their first neuropsychological evaluation. T-scores were computed for each domain and the MNC was applied to detect impairment among seronegative and seropositive groups. RESULTS: The MNC classified 6.26% of seronegative men as being impaired using a predetermined 5% false discovery rate. By contrast, the Frascati and the Gisslén criteria identified 24.54 and 11.36% of seronegative men as impaired. For seropositive men, the percentage impairment was 7.45, 25.73, and 11.69%, respectively, by the MNC, Frascati and Gisslén criteria. When we used seronegative men without medical comorbidities as the control group, the MNC, the Frascati and the Gisslén criteria identified 5.05, 27.07, and 4.21% of the seronegative men, and 4.34, 30.95, and 4.48% of the seropositive men as having cognitive impairment. For each method, serostatus was not associated with cognitive impairment. CONCLUSION: The MNC controls the false discovery rate and therefore avoids the low specificity that characterizes the Frascati and Gisslén criteria. More research is needed to evaluate the sensitivity of the MNC method in a seropositive population that may be sicker and older than the current study sample and that includes women.
BACKGROUND: Prevalence estimates of cognitive impairment in HIV disease vary widely. Here we used multivariate normative comparison (MNC) with identify individuals with impaired cognition, and to compare the results with those using the Frascati and Gisslén criteria. METHODS: The current project used data collected before October 2014 from bisexual/gay men from the Multicenter AIDS Cohort Study. A total of 2904 men (mean age 39.7 years, 52.7% seropositive) had complete data in six cognitive domains at their first neuropsychological evaluation. T-scores were computed for each domain and the MNC was applied to detect impairment among seronegative and seropositive groups. RESULTS: The MNC classified 6.26% of seronegative men as being impaired using a predetermined 5% false discovery rate. By contrast, the Frascati and the Gisslén criteria identified 24.54 and 11.36% of seronegative men as impaired. For seropositive men, the percentage impairment was 7.45, 25.73, and 11.69%, respectively, by the MNC, Frascati and Gisslén criteria. When we used seronegative men without medical comorbidities as the control group, the MNC, the Frascati and the Gisslén criteria identified 5.05, 27.07, and 4.21% of the seronegative men, and 4.34, 30.95, and 4.48% of the seropositive men as having cognitive impairment. For each method, serostatus was not associated with cognitive impairment. CONCLUSION: The MNC controls the false discovery rate and therefore avoids the low specificity that characterizes the Frascati and Gisslén criteria. More research is needed to evaluate the sensitivity of the MNC method in a seropositive population that may be sicker and older than the current study sample and that includes women.
Authors: Karl Goodkin; Eric N Miller; Christopher Cox; Sandra Reynolds; James T Becker; Eileen Martin; Ola A Selnes; David G Ostrow; Ned C Sacktor Journal: Lancet HIV Date: 2017-07-14 Impact factor: 12.767
Authors: R K Heaton; I Grant; N Butters; D A White; D Kirson; J H Atkinson; J A McCutchan; M J Taylor; M D Kelly; R J Ellis Journal: J Int Neuropsychol Soc Date: 1995-05 Impact factor: 2.892
Authors: L A Kingsley; R Detels; R Kaslow; B F Polk; C R Rinaldo; J Chmiel; K Detre; S F Kelsey; N Odaka; D Ostrow Journal: Lancet Date: 1987-02-14 Impact factor: 79.321
Authors: K Blackstone; D J Moore; D R Franklin; D B Clifford; A C Collier; C M Marra; B B Gelman; J C McArthur; S Morgello; D M Simpson; R J Ellis; J H Atkinson; I Grant; R K Heaton Journal: Clin Neuropsychol Date: 2012-06-18 Impact factor: 3.535
Authors: Brandon J Lew; Mikki D Schantell; Jennifer O'Neill; Brenda Morsey; Tina Wang; Trey Ideker; Susan Swindells; Howard S Fox; Tony W Wilson Journal: Cereb Cortex Date: 2021-07-05 Impact factor: 5.357
Authors: Natalia L Oliveira; Edward H Kennedy; Ryan Tibshirani; Andrew Levine; Eileen Martin; Cynthia Munro; Ann B Ragin; Leah H Rubin; Ned Sacktor; Eric C Seaberg; Andrea Weinstein; James T Becker Journal: AIDS Date: 2021-05-01 Impact factor: 4.177
Authors: Yang Qu; Andrea Weinstein; Zheng Wang; Yu Cheng; Lawrence Kingsley; Andrew Levine; Eileen Martin; Cynthia Munro; Ann B Ragin; Leah H Rubin; Ned W Sacktor; Eric C Seaberg; James T Becker Journal: AIDS Date: 2022-01-01 Impact factor: 4.177
Authors: Anna J Dreyer; Sam Nightingale; Jodi M Heaps-Woodruff; Michelle Henry; Hetta Gouse; Robert H Paul; Kevin G F Thomas; John A Joska Journal: J Neurovirol Date: 2021-07-09 Impact factor: 2.643